Search Results

You are looking at 1 - 3 of 3 items for :

  • pharmacokinetics x
  • Gastroenterology x
Clear All
Open access

Hirokazu Yamagami, Yu Nishida, Yasuaki Nagami, Shuhei Hosomi, Tomomi Yukawa, Koji Otani, Fumio Tanaka, Koichi Taira, Noriko Kamata, Tetsuya Tanigawa, Masatsugu Shiba, Toshio Watanabe and Yasuhiro Fujiwara

. VOIOSU T, BENGUŞ A, BĂLĂNESCU P, DINU R, VOIOSU A, BĂICUŞ C et al. Rapid fecal calprotectin testing predicts mucosal healing better than C-reactive protein and Serum tumor necrosis factor α in patients with ulcerative colitis. Rom J Intern Med. 2015; 53(3):253-60. 18. DOTAN I, RON Y, YANAI H, BECKER S, FISHMAN S, YAHAV L et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis. 2014; 20(12):2247-59. 19. BRANDSE JF, MATHÔT RA, VAN

Open access

Maria-Magdalena Leon-Constantin, Alexandra Maștaleru, Ovidiu Mitu, Madalina Zota, Teodor Vasilcu, Radu Gavril and Florin Mitu

, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects. AmJ Emerg Med. 2016;34(11S):26-32. 14. Choo WK, Fraser S, Padfield G et al. Dabigatran improves the efficiency of an elective direct current cardioversion service. Br J Cardiol 2014;21:29–32. 15. Cappato R, Ezekowitz MD, Klein AL et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35(47):3346-55. 16. Sakabe M, Yoshioka R, Fujiki A. Low APTT and BMI predicts the occurrence of ischemic stroke in patients with Atrial Fibrillation

Open access

Andreja Figurek, Vlastimir Vlatkovic, Dragan Vojvodic, Branislav Gasic and Milorad Grujicic

., AKITA W., KUYAMA T., TAKADA S., ASAI T., et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients – a single-center cohort study. Nephrol Dial Transplant 2012; 27 :345-51. 27. LIN JH. Bisphosponates: a review of their pharmacokinetic properties . Bone. 1996; 18 (2):75-85. 28. CONTR P., GUARNERI V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimen. The Oncologist.2004; 9 (Suppl 4): 28-37. 29. SHERRARD DJ., HERCZ G., PEI Y